BioNTech co-founders Özlem Türeci (L) and Uğur Şahin (Horst Galuschka/picture-alliance/dpa/AP Images)

June 5, 2022 12:30 PM EDTUpdated June 6, 08:27 AM

#ASCO22: BioNTech says mRNA vaccine safe in 15 of 16 patients with deadly pancreatic cancer

Kyle LaHucik

Senior Reporter

CHICAGO — Pandemic vaccine breakout BioNTech is back with more data on its individualized mRNA cancer jab known as autogene cevumeran in the most common …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO22: BioNTech says mRNA vaccine safe in 15 of 16 patients with deadly pancreatic cancer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

#AS­CO22: BioN­Tech says mR­NA vac­cine safe in 15 of 16 pa­tients with dead­ly pan­cre­at­ic can­cer

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#ASCO22: BioNTech says mRNA vaccine safe in 15 of 16 patients with deadly pancreatic cancer